ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 12 Jul 2022
Last Updated on 12 Jul 2022

A- A+

Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended: Osimertinib 40 mg and 80 mg tablets for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients whose disease has progressed on or after EGFR TKI therapy.
Subsidy status
Osimertinib 40 mg and 80 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. MAF assistance does not apply to osimertinib 40 mg or 80 mg tablets when used for adjuvant treatment of EGFR mutation-positive NSCLC after tumour resection, or for previously untreated locally advanced or metastatic EGFR mutation-positive NSCLC. *Clinical indications, subsidy class and MediShield Life claim limits for osimertinib are provided in the Annex.*

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

Osimertinib 40 mg and 80 mg tablets for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients whose disease has progressed on or after EGFR TKI therapy.

Subsidy status

Osimertinib 40 mg and 80 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

MAF assistance does not apply to osimertinib 40 mg or 80 mg tablets when used for adjuvant treatment of EGFR mutation-positive NSCLC after tumour resection, or for previously untreated locally advanced or metastatic EGFR mutation-positive NSCLC.

Clinical indications, subsidy class and MediShield Life claim limits for osimertinib are provided in the Annex.

Osimertinib for treating EGFR mutation-positive NSCLC (12 Jul 22) PES Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer (Published 12 July 2022)